Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Analyst Ratings
Moderate Buy
7 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARWR Stock 12 Month Forecast
Average Price Target
$37.25
▲(131.94% Upside)
| Highest Price Target$80.00 | Average Price Target$37.25 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$16.5
Hold
2.74%
Upside
Reiterated
08/08/25
Arrowhead Pharmaceuticals' overall stock score is driven by significant financial challenges and a mixed technical outlook. However, the positive sentiment from the earnings call, highlighting strong pipeline progress and financial performance, provides some optimism. The company's valuation remains a concern due to ongoing losses and lack of dividend yield.
Morgan Stanley
$29
Hold
80.57%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
H.C. Wainwright
$80
Buy
398.13%
Upside
Reiterated
08/06/25
Leerink Partners
―
Hold
―
Reiterated
07/28/25
UBS
$63→$12
Hold
-25.28%
Downside
Downgraded
07/21/25
Citi
$17
Hold
5.85%
Upside
Reiterated
07/20/25
Bernstein
―
Hold
―
Reiterated
06/19/25
B.Riley Financial
$38
Buy
136.61%
Upside
Reiterated
05/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Bank of America Securities
$41→$39
Buy
142.84%
Upside
Reiterated
05/12/25
Goldman Sachs
$26
Hold
61.89%
Upside
Reiterated
03/10/25
Chardan Capital
$60
Buy
273.60%
Upside
Reiterated
02/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$16.5
Hold
2.74%
Upside
Reiterated
08/08/25
Arrowhead Pharmaceuticals' overall stock score is driven by significant financial challenges and a mixed technical outlook. However, the positive sentiment from the earnings call, highlighting strong pipeline progress and financial performance, provides some optimism. The company's valuation remains a concern due to ongoing losses and lack of dividend yield.
Morgan Stanley
$29
Hold
80.57%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
H.C. Wainwright
$80
Buy
398.13%
Upside
Reiterated
08/06/25
Leerink Partners
―
Hold
―
Reiterated
07/28/25
UBS
$63→$12
Hold
-25.28%
Downside
Downgraded
07/21/25
Citi
$17
Hold
5.85%
Upside
Reiterated
07/20/25
Bernstein
―
Hold
―
Reiterated
06/19/25
B.Riley Financial
$38
Buy
136.61%
Upside
Reiterated
05/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Bank of America Securities
$41→$39
Buy
142.84%
Upside
Reiterated
05/12/25
Goldman Sachs
$26
Hold
61.89%
Upside
Reiterated
03/10/25
Chardan Capital
$60
Buy
273.60%
Upside
Reiterated
02/11/25
Best Analysts Covering Arrowhead Pharmaceuticals
1 Month
xxx
Success Rate
13/23 ratings generated profit
Average Return
-0.97%
reiterated a xxx
rating 21 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of -0.97% per trade.
3 Months
xxx
Success Rate
20/39 ratings generated profit
Average Return
+5.43%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 51.28% of your transactions generating a profit, with an average return of +5.43% per trade.
1 Year
Success Rate
18/39 ratings generated profit
Average Return
+23.22%
reiterated a buy rating 6 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +23.22% per trade.
2 Years
xxx
Success Rate
12/39 ratings generated profit
Average Return
+31.24%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of +31.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARWR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
8
6
7
8
4
Buy
1
2
2
3
2
Hold
8
10
12
15
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
18
21
26
16
Each month's total comprises the sum of three months' worth of ratings.
ARWR Financial Forecast
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 37.25.
What is ARWR’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 131.94% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy which is based on 7 buy ratings, 5 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s price target?
The average price target for Arrowhead Pharmaceuticals is 37.25. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $12.00. The average price target represents 131.94% Increase from the current price of $16.06.
The highest analyst price target is $80.00 ,the lowest forecast is $12.00. The average price target represents 131.94% Increase from the current price of $16.06.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.